Proctitis: rectal inflammation, causes, treatment and urgent symptoms

Proctitis is inflammation of the lining of the rectum, the final part of the large bowel. It can cause bleeding, mucus, pain and a persistent urge to pass stool. The cause may be inflammatory bowel disease, infection or another injury, so the right treatment depends on investigation. Radiation injury is also called radiation proctopathy. Confidence is high in the need for cause-specific assessment and urgent bleeding care, moderate in standard clinical pathways, and limited for supplement cures or one treatment for every subtype. NIDDK definition.

Table of contents

• Evidence summary
• What is proctitis and how do its subtypes differ?
• Proctitis symptoms, causes and diagnostic tests
• Cause-specific treatment for ulcerative and infectious proctitis
• Proctitis nutrition and probiotic-supplement evidence
• Remission, infection follow-up and treatment limits
• Rectal bleeding, dehydration and treatment warning signs
• Mesalazine, rectal formulations and medicine interactions
• Immune suppression, radiation and diverted-rectum assessment
• Your proctitis testing, treatment and follow-up plan
• Animal and laboratory proctitis research limits
• Funding and source roles
• Frequently asked questions
• Sources and funding notes

Evidence summary

Clinical guidance, human outcome research and funding independence answer different questions. The guidance below explains care; it does not independently reproduce the trials behind a medicine or supplement.

What is proctitis and how do its subtypes differ?

Ulcerative proctitis is ulcerative-colitis inflammation limited to the rectum. Crohn’s disease can also affect that area. Infectious proctitis may be short-lived, while IBD-related disease can relapse. Proctocolitis involves the rectum and more of the colon. These distinctions matter when deciding how far to investigate and whether local treatment is sufficient. NIDDK subtypes; CDC syndrome definitions.

Radiation proctopathy can occur during or after pelvic radiotherapy, including years later. Diversion proctitis can develop in a rectum left in place when stool leaves through a stoma. A history of either does not justify ignoring new symptoms: bleeding can still require assessment for another cause. Tell the clinician exactly which operation or cancer treatment you had. NIDDK radiation and diversion context.

Proctitis symptoms, causes and diagnostic tests

Common symptoms include urgency, tenesmus—the feeling that you need to pass stool even when the rectum may be empty—pain, blood, mucus or pus. Diarrhoea and constipation can both occur. Infection, reduced blood flow, injury or medicine effects may also be relevant. A symptom pattern alone cannot reliably separate these from IBD or other rectal disease. NIDDK symptoms and causes.

The history includes bowel disease, travel, recent antibiotics, radiotherapy, surgery and relevant sexual exposures. Examination and selected blood, stool or rectal tests help identify the cause; endoscopy may inspect the lining and obtain biopsies. A stool sample is not the same as a rectal swab. Ask which question each test answers, and how results will be communicated. NIDDK investigation pathway.

Sexual-health assessment should be respectful and based on exposure rather than assumptions about identity. Some infections can resemble IBD. Mpox, also called monkeypox, can cause anorectal pain or bleeding, sometimes with only a few lesions. Report a new rash or relevant contact promptly. Neither an exposure history nor one symptom proves which infection is present. CDC clinical approach; CDC anorectal symptom context.

Cause-specific treatment for ulcerative and infectious proctitis

For mild-to-moderate ulcerative proctitis, NICE’s clinical pathway starts with a topical aminosalicylate. Clinicians may add or change treatment if the response is insufficient, using a defined review and a time-limited steroid course where appropriate. Persistent or more severe disease needs specialist care. These recommendations apply to ulcerative disease, not every infection or cause of rectal bleeding. NICE NG130 pathway.

In infectious proctitis, treatment targets the suspected or identified organism and may need to begin while tests are pending. Antibiotic resistance, allergies and the person’s circumstances affect selection. Viral infections require a different approach. Do not reuse leftover antibiotics, copy someone else’s regimen or assume that anti-inflammatory rectal treatment clears an infection. CDC diagnosis and treatment guidance.

Radiation injury may need symptom-directed treatment or endoscopic control of persistent bleeding. Diversion disease requires review by the surgical team; restoring bowel continuity may be considered when feasible, while rectal medicines may be used when reconnection is not possible. Complications such as abscesses, fistulas or narrowing can require procedures. These decisions cannot be reduced to one self-treatment. NIDDK cause-specific care.

Proctitis nutrition and probiotic-supplement evidence

For IBD-related disease, protect nutrition rather than assuming that a restrictive diet cures inflammation. A food diary can help discuss symptom-related foods. Poor appetite, weight loss or difficulty eating deserves review; children need attention to growth. Supplement use should address a defined nutritional need and the actual treatment plan. Nutrition advice for ulcerative disease should not be presented as a cure for all proctitis. NIDDK IBD nutrition.

Probiotics are not interchangeable: a finding involving one strain or condition cannot establish another product’s effect. This review does not establish an independent probiotic cure for ulcerative, infectious, radiation or diversion proctitis. Safety is especially relevant with serious illness or immune suppression. NCCIH notes infection and contamination concerns in vulnerable people; discuss use with the treating team before adding a live-microbe product. NCCIH evidence and safety limits.

A supplement that makes stool feel different has not necessarily treated the rectal disease. Track bleeding, pain and urgency as well as bowel frequency, and use the clinical follow-up plan to assess improvement. If symptoms worsen after adding a product, report its full ingredient list and timing. Do not delay investigation while trialling a succession of “gut-healing” products.

Remission, infection follow-up and treatment limits

With chronic ulcerative disease, inducing remission and maintaining remission are separate decisions. NICE includes ongoing aminosalicylate options after improvement. Stopping all treatment as soon as bleeding settles may conflict with the agreed maintenance plan. Ask which medicine is temporary, which is ongoing, and what evidence will trigger reassessment. NICE remission and maintenance guidance.

With an infection, follow-up may include further testing and partner care to reduce reinfection or transmission. CDC recommends avoiding sexual contact until the relevant treatment requirements are completed and symptoms resolved, including partner treatment where indicated. The clinician should give infection-specific advice and discuss other-site testing or HIV prevention when relevant. Proctitis from a noninfectious cause does not automatically mean a partner is infected. CDC follow-up and partner guidance.

CDC’s live clinical directory still points to its 2021 STI guidance. That verifies the current directory reference, not that every evidence base was rewritten in 2026. Local resistance patterns and current product availability can change treatment choices. CDC current guidance directory.

Rectal bleeding, dehydration and treatment warning signs

Seek prompt assessment for blood, mucus or pus from the rectum, or severe abdominal pain. Heavy or non-stop bleeding, large clots or toilet water turning red requires emergency care. Black or dark-red stool also needs urgent assessment. Do not decide that bleeding is harmless because you already have an IBD or haemorrhoid diagnosis. NIDDK symptoms needing care; NHS bleeding triage.

Diarrhoea can contribute to dehydration. Persistent dizziness on standing, reduced urination, rapid breathing or unusual drowsiness needs urgent help. Confusion, difficulty waking or other shock signs requires emergency care. Use the local emergency number and follow the treating team’s hydration advice, especially with heart or kidney disease. NHS dehydration warnings.

Mesalazine can cause adverse effects that need assessment. A severe blistering or ulcerating rash requires emergency care and immediate medicine interruption as the NHS advises; breathing difficulty or swelling of the throat is an emergency. Changes in urine, fever or unexplained bruising also warrant urgent clinical contact. A new medicine problem should not simply be dismissed as an IBD flare. NHS mesalazine safety.

Mesalazine, rectal formulations and medicine interactions

Before mesalazine treatment, report other medicines, including NSAIDs, warfarin, azathioprine, mercaptopurine and laxatives. NHS guidance warns that combinations can affect treatment or side-effect risk. Herbal and supplement interactions are incompletely known. The pharmacist should review the whole list, rather than judging safety from the word “natural.” Do not independently stop a prescribed medicine. NHS interaction guidance.

Rectal and oral formulations have different instructions; the exact product matters. Do not swap mesalazine brands or forms without advice, or use a rectal product as if it were an oral one. If you cannot retain or use a prescribed rectal treatment, tell the team: they can review technique, tolerability and alternatives instead of assuming the condition is resistant. NHS formulation-specific use.

Immune suppression, radiation and diverted-rectum assessment

People with immune suppression, HIV or recent antibiotics may need a broader infection assessment. Pregnancy, childhood, major comorbidity and recent cancer treatment can alter treatment choices. Bring the details rather than assuming that a generic proctitis pathway fits every situation. Discuss sexual-health testing in private if that makes it easier to give an accurate history. CDC special considerations; NIDDK relevant history.

A diverted rectum can still become symptomatic even when stool leaves through a stoma. Ask the surgical team whether discharge is expected, which changes need assessment and whether there is a plan for the retained rectum. New bleeding after radiotherapy likewise needs a clear diagnostic plan; the history is a clue rather than the final explanation. NIDDK diversion and radiation categories.

Your proctitis testing, treatment and follow-up plan

Prepare a timeline of bleeding, pain, stool frequency, urgency, discharge and fever. Include previous infection treatment, current IBD medicines, antibiotics, relevant exposures and radiation/surgical records. Ask whether the inflammation is limited to the rectum, what the likely cause is, and which results remain pending.

A written plan should explain how to use the exact treatment, when review occurs, what improvement is expected and whom to contact if it fails. For endoscopy, follow the service’s preparation and medicine instructions and arrange required recovery support after sedation. Confirm how biopsy results will reach you. This guide gives no antibiotic doses, rectal-treatment schedule or self-directed bowel preparation. NHS procedure preparation.

Animal and laboratory proctitis research limits

Laboratory models can study inflammation, microbial effects or radiation injury. A favourable cell response does not show that a product treats human proctitis or prevents transmission of an infection. Human studies need the relevant subtype, meaningful symptom and tissue outcomes, adequate harms reporting and transparent finances. No animal or in-vitro result supports the independent treatment verdict here.

Funding and source roles

Drug, diagnostic, endoscopy and supplement businesses can earn revenue from proctitis care. Those incentives do not establish that a particular recommendation is false, but they require scrutiny. The original CDC guideline reports contributor ties including Hologic, Lupin, Gilead, Roche and other companies; CDC public funding does not remove those interests. NICE and government patient pages explain clinical pathways without financially clearing every source trial. Corporate-funded efficacy is excluded from the independent verdict, and no product is endorsed. Sources are concentrated in the US and UK; local treatment, privacy and partner-care arrangements differ.

Frequently asked questions

Does proctitis always mean ulcerative colitis?

No. It describes rectal inflammation; infection, radiation/diversion-related disease and other injuries must be considered.

Does rectal bleeding prove proctitis?

No. Several conditions cause bleeding, including problems that need urgent care. Examination and appropriate tests determine the cause.

Is proctitis contagious?

Some infectious causes can be transmitted, while IBD and radiation injury are not contagious. Follow infection-specific advice rather than making assumptions.

Why was a rectal swab requested?

It can test for infections at that site. A stool or urine test may not answer the same question.

Can probiotics replace rectal mesalazine?

An independent replacement benefit is not established here. Discuss intolerance or practical problems with prescribed treatment instead of substituting a supplement.

Why do I need care if my rectum is diverted?

A retained rectum can develop diversion-related inflammation and symptoms. The surgical team should provide a plan for bleeding or discharge.

Sources and funding notes

Primary clinical pages and the original CDC guideline, including its financial statements, were checked. CDC’s live directory still names its 2021 STI guideline; this is not described as a newly rewritten 2026 guideline. NICE direct retrieval was blocked, so official indexed recommendations were checked and the access limit is disclosed. Older NIH/probiotic and NHS bleeding review dates remain visible in the scorecard. Funding tiers and credibility grades are provisional; neither clinical guidelines nor public education clear all underlying drug trials. No corporate efficacy, animal result or personalised regimen is used as an independent verdict.

1. NIDDK: proctitis definition facts — Definition, subtypes and complications; no prevalence figures adopted.
2. NIDDK: proctitis symptoms causes — Symptoms and non-interchangeable causes; not a symptom-based self-diagnosis.
3. NIDDK: proctitis diagnosis — History, rectal tests and endoscopy/biopsy context.
4. NIDDK: proctitis treatment — Radiation/diversion treatment categories; current infection and ulcerative-proctitis care checked against their own guidance.
5. CDC: proctitis, proctocolitis and enteritis, 2021 — Clinical diagnosis, targeted treatment and infection-related follow-up; no independent drug efficacy ranking.
6. CDC MMWR original STI guideline and disclosures, 2021 — Original financial provenance and non-stigmatising history-taking principles; no corporate trial effect adopted.
7. CDC clinical-guidance directory, live 2026 check — Verifies that CDC still points to its 2021 guideline; does not imply every recommendation was newly revised in 2026.
8. CDC: about sexually transmitted infections — Testing, prevention and confidential partner-care context.
9. CDC: mpox/monkeypox clinical signs — Anorectal symptom differential; no diagnosis from a rash photograph or exposure alone.
10. NICE NG130: ulcerative-proctitis clinical guidance — Cause-specific conventional ulcerative-proctitis pathway; no personal regimen or independently cleared comparative efficacy.
11. NIDDK: ulcerative-colitis nutrition — Nutrition and symptom-food diary context for IBD-related proctitis only.
12. NCCIH: probiotics — Strain-specific uncertainty and vulnerable-person safety; no broad proctitis cure.
13. NHS: about mesalazine — Drug-class and formulation context for appropriate IBD care only.
14. NHS: mesalazine use — Formulation-specific instructions; no independent dose or brand switch.
15. NHS: mesalazine adverse effects — Urgent medicine-related safety; not a complete adverse-event list.
16. NHS: mesalazine interactions — Drug/supplement medicine-review context.
17. NHS: rectal bleeding — Emergency and urgent bleeding triage; April 2023 review with due date passed.
18. NHS: dehydration, May 2026 — Urgent dehydration and shock warning signs.
19. NHS: endoscopy, October 2026 — Preparation and follow-up instructions.

Educational information reviewed 4 October 2026. This guide supports an informed clinical discussion; it does not diagnose an individual or provide a personal treatment regimen.